CY1108282T1 - Χρηση λιποπεπτιδιου ή λιποπρωτεϊνης ως ανοσοενισχυτικο σε θεραπευτικο ή προφυλακτικο εμβολιασμο - Google Patents

Χρηση λιποπεπτιδιου ή λιποπρωτεϊνης ως ανοσοενισχυτικο σε θεραπευτικο ή προφυλακτικο εμβολιασμο

Info

Publication number
CY1108282T1
CY1108282T1 CY20081100896T CY081100896T CY1108282T1 CY 1108282 T1 CY1108282 T1 CY 1108282T1 CY 20081100896 T CY20081100896 T CY 20081100896T CY 081100896 T CY081100896 T CY 081100896T CY 1108282 T1 CY1108282 T1 CY 1108282T1
Authority
CY
Cyprus
Prior art keywords
glu
adjuvant
mucosal
vaccination
therapeutic
Prior art date
Application number
CY20081100896T
Other languages
English (en)
Inventor
Carlos Alberto Guzman
Peter MÜHLRADT
Original Assignee
Helmholtz-Zentrum für Infektionsforschung GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz-Zentrum für Infektionsforschung GmbH filed Critical Helmholtz-Zentrum für Infektionsforschung GmbH
Publication of CY1108282T1 publication Critical patent/CY1108282T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Προτείνεται η χρήση λιποπεπτιδίων και λιποπρωτεινών ως βλεννογονικά ανοσοενισχυτικά για ποικίλους εμβολιασμούς μέσω του βλεννογόνου, ιδίως μέσω της ενδορινικής οδού. Τα λιποπεπτίδια αποτελούν πεπτίδια ή πρωτεΐνες υποκατεστημένα με 2,3-διακυλοξυ(2R)-προπύλιο στην αμινοτερματική κυστεΐνη πεπτιδίου ή πρωτεΐνης, κατά προτίμηση S-(2,3-δισπαλμιτοϋλοξυ-(2R)-προπυλο)κυστεϊνυλο-πεπτίδια προερχόμενα από μυκοπλάσματα. Τα εν λόγω πεπτίδια είναι πολύ δραστικά ακόμη και σε μικρές δόσεις και οδηγούν σε καλά αποτελέσματα ανοσοποίησης και σε αύξηση, μεταξύ άλλων, του IgA επιπέδου.
CY20081100896T 2002-04-04 2008-08-22 Χρηση λιποπεπτιδιου ή λιποπρωτεϊνης ως ανοσοενισχυτικο σε θεραπευτικο ή προφυλακτικο εμβολιασμο CY1108282T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02007640 2002-04-04
EP03745782A EP1490106B1 (de) 2002-04-04 2003-04-03 Verwendung eines lipopeptids oder lipoproteins als adjuvans bei therapeutischer oder prophylaktischer vakzinierung

Publications (1)

Publication Number Publication Date
CY1108282T1 true CY1108282T1 (el) 2014-02-12

Family

ID=28685840

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100896T CY1108282T1 (el) 2002-04-04 2008-08-22 Χρηση λιποπεπτιδιου ή λιποπρωτεϊνης ως ανοσοενισχυτικο σε θεραπευτικο ή προφυλακτικο εμβολιασμο

Country Status (12)

Country Link
US (2) US20050276813A1 (el)
EP (2) EP1987841A1 (el)
AT (1) ATE396740T1 (el)
AU (1) AU2003226777B2 (el)
CA (1) CA2480196C (el)
CY (1) CY1108282T1 (el)
DE (1) DE50309916D1 (el)
DK (1) DK1490106T3 (el)
ES (1) ES2307958T3 (el)
PT (1) PT1490106E (el)
SI (1) SI1490106T1 (el)
WO (1) WO2003084568A2 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19652586A1 (de) * 1996-12-17 1998-06-18 Biotechnolog Forschung Gmbh Dhc-Peptid und Mittel
AU2006259630B2 (en) 2005-06-13 2011-10-27 Cleveland Biolabs, Inc. Methods of protecting against apoptosis using lipopeptides
EP1776963A1 (en) 2005-10-19 2007-04-25 Gbf-Gesellschaft Für Biotechnologische Forschung Mbh Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
EP1787660A1 (en) 2005-11-22 2007-05-23 GBF Gesellschaft für Biotechnologische Forschung mbH New adjuvants on the basis of bisacyloxypropylcysteine conjugates and their uses in pharmaceutical compositions
US8426163B2 (en) * 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US20110171259A1 (en) * 2008-09-05 2011-07-14 Martin Gagne Novel Compositions and Adjuvants
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
US8658176B2 (en) * 2009-06-22 2014-02-25 National Health Research Institutes Lipidated tumor-associated antigens and immunotherapeutic compositions
DE102009034779A1 (de) 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
EP2338521A1 (en) * 2009-12-28 2011-06-29 Helmholtz-Zentrum für Infektionsforschung GmbH Lipopeptide- and lipoprotein-conjugates and its use
JP2013542928A (ja) * 2010-09-30 2013-11-28 フランバックス ソチエタ レスポンサビリタ リミテ ビロソーム粒子の生成
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
DE102011018499A1 (de) 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
JP5650780B2 (ja) 2012-04-04 2015-01-07 日東電工株式会社 ワクチン組成物
DE102016005550A1 (de) * 2016-05-09 2017-11-09 Emc Microcollections Gmbh Adjuvans zur lnduzierung einer zellulären lmmunantwort
WO2019035605A2 (ko) * 2017-08-16 2019-02-21 주식회사 차백신연구소 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도
KR102098097B1 (ko) * 2017-08-16 2020-05-26 주식회사 차백신연구소 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022343A1 (en) * 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
DE19652586A1 (de) * 1996-12-17 1998-06-18 Biotechnolog Forschung Gmbh Dhc-Peptid und Mittel
DE19745522C2 (de) * 1997-10-15 2001-03-22 Daimler Chrysler Ag Vorrichtung zur Betätigung eines Gaswechselventiles einer Hubkolbenbrennkraftmaschine
DE19822820A1 (de) * 1998-05-20 1999-11-25 Biotechnolog Forschung Gmbh Pharmazeutisches Präparat zur Wundbehandlung

Also Published As

Publication number Publication date
US10905761B2 (en) 2021-02-02
DK1490106T3 (da) 2008-10-27
US20050276813A1 (en) 2005-12-15
AU2003226777A1 (en) 2003-10-20
ES2307958T3 (es) 2008-12-01
SI1490106T1 (sl) 2009-02-28
ATE396740T1 (de) 2008-06-15
AU2003226777B2 (en) 2008-05-29
CA2480196C (en) 2015-05-12
EP1490106B1 (de) 2008-05-28
US20160256542A1 (en) 2016-09-08
WO2003084568A2 (de) 2003-10-16
EP1987841A1 (de) 2008-11-05
WO2003084568A3 (de) 2003-12-31
EP1490106A2 (de) 2004-12-29
CA2480196A1 (en) 2003-10-16
DE50309916D1 (de) 2008-07-10
PT1490106E (pt) 2008-09-05

Similar Documents

Publication Publication Date Title
CY1108282T1 (el) Χρηση λιποπεπτιδιου ή λιποπρωτεϊνης ως ανοσοενισχυτικο σε θεραπευτικο ή προφυλακτικο εμβολιασμο
RU2220978C2 (ru) Пептид, индуцирующий образование антител, которые реагируют с двумя различными изолятами вррсс (варианты), иммуногенная композиция, вакцина для профилактики заражения репродуктивно-респираторным синдромом свиней, антитело, диагностический набор (варианты)
Zeng et al. Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys
Moyle et al. Self-adjuvanting lipopeptide vaccines
US6764682B1 (en) Adjuvant compositions containing more than one adjuvant
CN1688606B (zh) 含有辅助t细胞和b细胞表位的新的免疫原性脂肽
RU2375374C2 (ru) Домены и эпитопы менингококкового белка nmb1870
BR0211437A (pt) Vacinas que compreendem adjuvantes de alumìnio e histidina
GB2439474A (en) LI-Key/Antigenic epitope hybrid peptide vaccines
Muller et al. Antigenic properties and protective capacity of a cyclic peptide corresponding to site A of influenza virus haemagglutinin
RU2007145052A (ru) Композиции пептидного конъюгата и способы для профилактики и лечения болезни альцгеймера
NO20045021L (no) Immunologiske metoder og preparater for behandling av Alzheimers sykdom
JP2005060406A (ja) ワクチン用免疫原性ｌｈｒｈペプチド構築体および合成普遍免疫刺激器
US20090123488A1 (en) Compositions and methods for the treatment and prophylaxis of Alzheimer's disease
YU24004A (sh) Interleukin-12 kao adjuvant veterinarske vakcine
WO2006076587A3 (en) Peptides for delivery of mucosal vaccines
Zeng et al. Lipidation of intact proteins produces highly immunogenic vaccine candidates
Bessler et al. Bacterial cell wall components as immunomodulators—I. Lipopeptides as adjuvants for parenteral and oral immunization
WO2004022092A3 (en) Flagellin peptides as adjuvants for vaccines
JP5746970B2 (ja) ゴナドトロピン放出ホルモン（ｇｎｒｈ）変異体の組合せを免疫原として使用する医薬組成物
KR20190125997A (ko) 신규의 펩타이드 기재 pcsk9 백신
CA2696068A1 (en) Compositions and methods for the treatment and prophylaxis of hypertension
TNSN08184A1 (en) Chimeric antigens and vaccines
NZ515330A (en) Lawsonia derived gene and related OmpH polypeptides, peptides and proteins and their uses
EP3727372A1 (en) Administration of a tlr2 agonist for the treatment or prevention of a respiratory condition associated with an infectious agent